Literature DB >> 11034632

Clinical experience with retreatment for palliation.

D E Morris1.   

Abstract

Every radiation oncologist is faced occasionally with the need to consider reirradiation for palliation. Because reirradiation has the potential to exceed normal tissue tolerances, there is a need to have information on the efficacy and toxicity of retreatment. This article reviews the reirradiation literature and provides guidance to clinicians with regard to the risks, benefits, and side effects of retreatment. Copyright 2000 by W.B. Saunders Company.

Entities:  

Mesh：

Year:  2000        PMID： 11034632     DOI： 10.1053/s1053-4296(00)80039-9

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN： 1053-4296            Impact factor:   5.934


  7 in total

1.  Use of normal tissue complication probability models in the clinic.

Authors:  Lawrence B Marks; Ellen D Yorke; Andrew Jackson; Randall K Ten Haken; Louis S Constine; Avraham Eisbruch; Søren M Bentzen; Jiho Nam; Joseph O Deasy
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-01       Impact factor: 7.038

2.  Re-irradiation combined with capecitabine in locally recurrent squamous cell carcinoma of the head and neck. A prospective phase II trial.

Authors:  L Vormittag; C Lemaire; D Radonjic; G Kornek; E Selzer
Journal:  Strahlenther Onkol       Date:  2012-02-10       Impact factor: 3.621

3.  Pulsed low-dose rate radiotherapy has an improved therapeutic effect on abdominal and pelvic malignancies.

Authors:  Xin Wen; Hui Qiu; Zhiying Shao; Guihong Liu; Nianli Liu; Aoxing Chen; Xingying Zhang; Xin Ding; Longzhen Zhang
Journal:  J Zhejiang Univ Sci B       Date:  2021 Sept 15       Impact factor: 3.066

4.  Three-dimensional conformal reirradiation for locoregionally recurrent lung cancer previously treated with radiation therapy.

Authors:  Gil Ja Huh; Seong Soon Jang; Suk Young Park; Jae Hyuk Seo; Eun Youn Cho; Ji Chan Park; Young Jun Yang
Journal:  Thorac Cancer       Date:  2014-07-03       Impact factor: 3.500

5.  Retreatment with radiotherapy for symptomatic bone, brain or visceral metastases.

Authors:  R Hernanz; A Montero; E Fernandez-Lizarbe; A Polo; A Ramos
Journal:  Clin Transl Oncol       Date:  2012-07-20       Impact factor: 3.405

6.  Use of Pulsed Low-Dose Rate Radiotherapy in Refractory Malignancies.

Authors:  Jing Yan; Ju Yang; Yang Yang; Wei Ren; Juan Liu; Shanbao Gao; Shuangshuang Li; Weiwei Kong; Lijing Zhu; Mi Yang; Xiaoping Qian; Baorui Liu
Journal:  Transl Oncol       Date:  2018-01-04       Impact factor: 4.243

7.  Re-irradiation: outcome, cumulative dose and toxicity in patients retreated with stereotactic radiotherapy in the abdominal or pelvic region.

Authors:  Huda Abusaris; M Hoogeman; Joost J Nuyttens
Journal:  Technol Cancer Res Treat       Date:  2012-05-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.